IGF-1 LR3 Benefits: Bodybuilding Claims vs Evidence
IGF-1 LR3 benefits: what the long-acting analogue is, why claims outrun evidence, hypoglycaemia risk, and user reports. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
IGF-1 LR3 is an engineered IGF-1 analogue with an extended half-life, made mainly for cell-culture work. It has no approved human use; the approved IGF-1 drug (mecasermin) treats rare growth-factor deficiency. Muscle-growth benefits are forum claims, not trial results. Known risks of IGF-1 activity include low blood sugar, and growth-factor signalling raises theoretical tumour-growth concerns. WADA prohibits it in sport. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the IGF-1 LR3 reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is IGF-1 LR3 approved?
- No. It is a research reagent. Mecasermin is the approved IGF-1 medicine for specific deficiencies.
- What are IGF-1 LR3 risks?
- Hypoglycaemia is a key concern; long-term human safety data do not exist.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.